Zhougui Ling
Impact in
-
- Pleural and Pulmonary Diseases
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Diagnosis and Treatment 5
- Chronic Obstructive Pulmonary Disease (COPD) Research 1
- Oncology 4
- Lung Cancer Research Studies 2
- Cancer Immunotherapy and Biomarkers 1
- Co-authors
- Jin-Liang Kong (2 shared papers)Yiqiang Chen (4 shared papers)Chunmei Wang (1 shared paper)Youping Deng (4 shared papers)Shuangqi Cai (2 shared papers)Hamid Reza Arabnia (1 shared paper)Yuanyuan Fu (1 shared paper)Rui Jun Su (3 shared papers)
- Journals
- Disease Markers (3 papers)Frontiers in Oncology (3 papers)PLoS ONE (3 papers)Frontiers in Pharmacology (2 papers)BMC Bioinformatics (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Zhougui Ling
21 papers receiving 260 citations
Peers
Comparison fields: 5 of 50
- Pulmonary and Respiratory Medicine 99
- Clinical Biochemistry 11
- Oncology 49
- Cancer Research 22
- Otorhinolaryngology 6
Countries citing papers authored by Zhougui Ling
This map shows the geographic impact of Zhougui Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhougui Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhougui Ling more than expected).
Fields of papers citing papers by Zhougui Ling
This network shows the impact of papers produced by Zhougui Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhougui Ling. The network helps show where Zhougui Ling may publish in the future.
Co-authors
The 25 scholars most cited alongside Zhougui Ling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 64 | |
| 2 | 2015 | 47 | |
| 3 | 2020 | 33 | |
| 4 | 2019 | 17 | |
| 5 | 2021 | 15 | |
| 6 | 2020 | 14 | |
| 7 | High mobility group protein B1 (HMGB1) interacts with receptor for advanced glycation end products (RAGE) to promote airway smooth muscle cell proliferation through ERK and NF-κB pathways. | 2019 | 13 |
| 8 | 2021 | 13 | |
| 9 | 2016 | 11 | |
| 10 | 2016 | 7 | |
| 11 | LncRNA TGFB2-AS1 regulates lung adenocarcinoma progression via act as a sponge for miR-340-5p to target EDNRB expression. | 2020 | 5 |
| 12 | 2021 | 5 | |
| 13 | 2022 | 4 | |
| 14 | 2024 | 4 | |
| 15 | 2021 | 3 | |
| 16 | 2017 | 2 | |
| 17 | 2022 | 2 | |
| 18 | 2024 | 2 | |
| 19 | 2024 | 1 | |
| 20 | 2025 | 1 |
About Zhougui Ling
Zhougui Ling is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Clinical Biochemistry, Molecular Biology and Cancer Research, having authored 25 papers that have together received 264 indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (5 papers), RNA modifications and cancer (5 papers), Lung Cancer Research Studies (2 papers), Cancer-related molecular mechanisms research (2 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (1 paper), Antifungal resistance and susceptibility (1 paper), Radiomics and Machine Learning in Medical Imaging (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (99 citations), Clinical Biochemistry (11 citations), Oncology (49 citations), Cancer Research (22 citations) and Otorhinolaryngology (6 citations). Zhougui Ling has collaborated with scholars based in China and United States. Frequent co-authors include Jin-Liang Kong, Yiqiang Chen, Chunmei Wang, Youping Deng, Shuangqi Cai, Hamid Reza Arabnia, Yuanyuan Fu, Rui Jun Su, Jifei Chen and Xiaomou Wei. Their work appears in journals such as Disease Markers, Frontiers in Oncology, PLoS ONE, Frontiers in Pharmacology and BMC Bioinformatics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.